Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion Avidity expects to separate its early-stage precision cardiology programs into a ...
SAN DIEGO, Sept. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback